Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients …
Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
the disease becomes resistant to androgen-deprivation therapy, treatment options are …
ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate …
C Hackenbruch, JS Heitmann, JS Walz, B Federmann… - 2023 - ascopubs.org
TPS5114 Background: Bispecific antibodies (bsAbs), alike CAR T cells, are not yet
successful in solid tumors. Recently we developed a PSMAxCD3 bsAb termed CC-1 in an …
successful in solid tumors. Recently we developed a PSMAxCD3 bsAb termed CC-1 in an …
Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate …
MN Stein, J Zhang, WK Kelly, DR Wise, K Tsao… - 2023 - ascopubs.org
154 Background: Pts with mCRPC have a poor prognosis with limited treatment options,
including minimal response to immunotherapies. REGN5678 is a first-in-class, full-length …
including minimal response to immunotherapies. REGN5678 is a first-in-class, full-length …
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant …
J Zhang, MN Stein, WK Kelly, CK Tsao, GS Falchook… - 2021 - ascopubs.org
TPS174 Background: Bispecific antibodies (bsAbs) are emerging as a protein-based
therapeutic strategy for directing T-cell-mediated cytotoxicity in a tumor antigen-specific …
therapeutic strategy for directing T-cell-mediated cytotoxicity in a tumor antigen-specific …
Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer
EA Lim, MT Schweizer, KN Chi, R Aggarwal… - Clinical Genitourinary …, 2023 - Elsevier
Introduction Cancer immunotherapies have limited efficacy in prostate cancer due to the
immunosuppressive prostate microenvironment. Prostate specific membrane antigen …
immunosuppressive prostate microenvironment. Prostate specific membrane antigen …
[HTML][HTML] Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
K Dang, G Castello, SC Clarke, Y Li… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Therapeutic options currently available for metastatic castration-resistant
prostate cancer (mCRPC) do not extend median overall survival> 6 months. Therefore, the …
prostate cancer (mCRPC) do not extend median overall survival> 6 months. Therefore, the …
Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate …
EA Lim, MT Schweizer, KN Chi, RR Aggarwal… - 2022 - ascopubs.org
279 Background: PSMA expression is increased in response to anti-androgen therapies and
is a promising therapeutic target for the treatment of prostate cancer (PCa). JNJ-081 is a …
is a promising therapeutic target for the treatment of prostate cancer (PCa). JNJ-081 is a …
610P BXCL701-1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer …
P Monk, J Zhang, D Costin, DP Petrylak… - Annals of …, 2021 - annalsofoncology.org
Background BXCL701 (talabostat), an oral small molecule inhibitor of dipeptidyl peptidases—
primarily DPP8/9—triggers the inflammasome to alert and prime immune cells, leading to …
primarily DPP8/9—triggers the inflammasome to alert and prime immune cells, leading to …
Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer …
MC Markowski, D Kilari, MA Eisenberger, RR McKay… - 2021 - ascopubs.org
TPS5094 Background: CCW702 is a novel bispecific antibody comprised of a small
molecule imaging agent ligand (DUPA) with specificity for prostate specific membrane …
molecule imaging agent ligand (DUPA) with specificity for prostate specific membrane …
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
KJ Pienta, JP Machiels, D Schrijvers, B Alekseev… - Investigational new …, 2013 - Springer
Background CC-chemokine ligand 2 (CCL2) promotes tumor growth by angiogenesis,
macrophage infiltration and tumor invasion, and distant metastasis. Carlumab (CNTO 888) is …
macrophage infiltration and tumor invasion, and distant metastasis. Carlumab (CNTO 888) is …
相关搜索
- bispecific antibody prostate cancer
- multicentre phase psmaxcd3 antibody
- preliminary efficacy psmaxcd3 antibody
- multicentre phase preliminary efficacy
- prostate carcinoma psmaxcd3 antibody
- multicentre phase prostate carcinoma
- prostate carcinoma preliminary efficacy
- psma and cd3 prostate cancer
- psma and cd3 molecule antibody
- cc chemokine prostate cancer
- pd 1 prostate cancer
- molecule antibody prostate cancer